Introduction: Cervical cancer, predominantly caused by human papillomavirus (HPV), is a common malignancy in women. Distinct histological subtypes, such as squamous cell carcinomas (SCC) and adenocarcinomas (AC), exhibit different characteristics and treatment responses. Immune checkpoint molecules, including programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), contribute to immune evasion. This study aims to investigate PD-L1 expression in SCC and AC of cervix and explore its association with clinical features. Methods: This cross-sectional study was conducted on samples from 2016 to 2022 in Shahid Beheshti University of Medical Sciences-affiliated hospitals, Tehran, Iran. Paraffin-embedded samples of histologically confirmed cervical cancers (48 SCC - 16 AC) were analyzed, and clinical data were extracted from medical records. PD-L1 expression was assessed using immunohistochemistry, and the combined positive score was utilized. Statistical analyses included T-tests, Chi-Square tests, and non-parametric equivalents. Results: PD-L1 expression tended to be higher in SCC cases, although the difference was not statistically significant. Positive PD-L1 expression was more common in SCC cases. However, no significant correlation was observed between PD-L1 expression and clinical features in either subgroup. Mean age and clinical characteristics did not significantly differ between the SCC and AC groups. Conclusion: This study investigated PD-L1 expression in SCC and AC of the cervix and its relationship with clinical features. Although SCC cases tended to exhibit higher PD-L1 expression, the difference was not statistically significant. Further research is warranted to elucidate the role of PD-L1 in cervical cancer and its potential implications for immunotherapy.